| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| C.D. Smith Drug Company |
| 3907 S. 48th Terrace P.O. Box 789, St. Joseph, MO 64503 * (816) 232-5471 |
| The company is a leading regional full-time, full-service wholesale distributor of pharmaceuticals and related products. |
| Manager | Tier | Phone |
| Donaldson, Lufkin & Jenrette Securities Corp. | Lead Manager | (212) 371-0641 |
| BT Alex Brown | Co-manager | (410) 727-1700 |
| Wheat First Union | Co-manager |
| NASNTL: | CDSH | Wholesale: | SIC 5122 | |
| Type of Shares: | Common Shares | Filing Date: | 6/5/98 | |
| U.S. Shares Filed: | 4,750,000 | Filing Range: | $15.00 - $17.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $76,000,000 | |
| Primary Shares: | 3,500,000 | Expenses: | - | |
| Secondary Shares: | 1,250,000 | Post-IPO Shares: | ||
| Employees: | 318 |
| Issuer's Law Firm: | Blackwell Sanders Matheny Weary & Lombardi |
| Bank's Law Firm: | Gardere & Wynne |
| Registrar/Transfer Agent: | UMB Bank N.A. MO |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 2/28/98 | 2/28/98 | ||||
| Revenue: | $544.09 | Assets: | $168.70 | ||
| Net Income: | $4.00 | Curr Assets: | $134.00 | ||
| EPS: | Liabilities: | $161.57 | |||
| Prior EPS: | Curr Liab: | $66.09 | |||
| Cash Flow/Oper: | -$5.90 | Equity: | $7.13 | ||
| Cash Flow/Fin: | $35.64 | Cash: | $0.04 | ||
| Cash Flow/Inv: | -$29.71 | Working Cap: | $67.91 | ||
| Competition |
| The wholesale distribution of pharmaceuticals, health and beauty aids and other health care products is highly competitive. The Company competes with numerous national and regional distributors, some of which are larger and have substantially greater financial resources than the Company. In addition, the Company competes with numerous distributors, direct-selling manufacturers and other specialty distributors. Competitive factors include price, service and delivery, credit terms, breadth of product line, customer support and marketing programs. A price decrease by a competitor, or an increase in the other competitive factors, could have a material adverse effect on the Company. There can be no assurance that the Company will not encounter increased competition in the future that could adversely affect the Company's business. |
| Business Plan |
| The Company's objective is to build on its position as a leading regional wholesale distributor to become a national pharmaceutical services company. The principal elements of the Company's strategy are as follows: (I) Provide High Levels of Customer Service, (ii) Increase Sales from Existing Facilities, (iii) Continue Selective Acquisitions, (iv) Offer Broad Line of Products and Services and (v) Expand Pharmaceutical Services. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay certain indebtedness. |